Fractionated stereotactic radiotherapy of vestibular schwannomas accelerates hearing loss

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

  • Rune Rasmussen
  • Magnus Claesson
  • Sven-Eric Stangerup
  • Henrik Roed
  • Ib Jarle Christensen
  • Per Caye Thomasen
  • Juhler, Marianne
To evaluate long-term tumor control and hearing preservation rates in patients with vestibular schwannoma treated with fractionated stereotactic radiotherapy (FSRT), comparing hearing preservation rates to an untreated control group. The relationship between radiation dose to the cochlea and hearing preservation was also investigated.
OriginalsprogEngelsk
TidsskriftInternational Journal of Radiation Oncology, Biology, Physics
Vol/bind83
Udgave nummer5
Sider (fra-til)e607-11
ISSN0360-3016
DOI
StatusUdgivet - 2012

ID: 48483250